Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 6/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.33 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16543489 | 0.78 | KDM4E (0.50) | CYP1A2PKMKDM4ENPC1RAB9A | |
| SCHEMBL15471366 | 0.74 | S1PR1 (0.41) | PIK3CDPIK3R1PIK3CAPIK3CBPIK3CG | |
| SCHEMBL15599482 | 0.72 | BRD4 (0.40) | NPC1RAB9A | |
| SCHEMBL13609458 | 0.72 | PTGS1 (0.42) | CNR2CYP1A2KDM4ENPC1RAB9A | |
| SCHEMBL14369743 | 0.72 | KDM4E (0.53) | CYP1A2PKMMAPK1KDM4ENPC1 | |
| SCHEMBL3858280 | 0.72 | RAB9A (0.61) | KDM4ENPC1RAB9A | |
| SCHEMBL2612639 | 0.71 | NPC1 (0.49) | CYP1A2DGAT1KDM4ENPC1RAB9A | |
| SCHEMBL16997526 | 0.71 | TP53 (0.63) | CYP1A2PKMMAPK1KDM4ENPC1 | |
| SCHEMBL15879031 | 0.71 | PIK3CB (0.39) | CNR2CYP1A2PIK3CDPIK3R1PIK3CA | |
| SCHEMBL16997502 | 0.71 | KDM4E (0.47) | CNR2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9505749-B2 | Quinazolinone compounds and derivatives thereof | AMGEN INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-20150225396-A1 | Quinazolinone Compounds and Derivatives Thereof | AMGEN INC. | 2015-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225396-A1 | Quinazolinone Compounds and Derivatives Thereof | TNKS, TPI1, TNKS1BP1 | CNR2 4597/4885CYP1A2 1356/4885PIK3CD 636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.